Existing data support a modest association between cigarette smoking and incident colorectal cancer (CRC) overall. In this study, we evaluated associations between cigarette smoking and CRC risk stratifi ed by KRAS mutation status, using data and tissue resources from the Iowa Women ' s Health Study (IWHS).
INTRODUCTION
Colorectal cancer (CRC) is the fourth most common incident and second most common fatal malignancy in the United States, with ~ 140,000 new diagnoses recorded and nearly 50,000 deaths attributed to CRC each year ( 1 ) . Given this burden of disease, further understanding of common, potentially modifi able CRC risk factors represents an important public health priority.
Despite widespread tobacco control eff orts, about one in fi ve US adults still characterize themselves as active cigarette smokers ( 2 ) . Pooled analyses of data from numerous observational studies demonstrate increased risks for both benign and malignant colorectal neoplasia among cigarette smokers, as compared with non-smokers ( 3, 4 ) . Interestingly, our group ( 5 ) and others ( 6 -15 ) have reported that cigarette smoking appears to be associated with distinct, molecularly defi ned CRC subtypes, although the spectrum of genetic alterations and epigenetic modifi cations involved in smoking-related CRC risk remains incompletely described.
Th e KRAS oncogene has been commonly implicated in colorectal carcinogenesis, with somatic mutations identifi ed in 30 -40 % of sporadic CRCs ( 16, 17 ) . Tumor testing for KRAS mutations has been endorsed as an adjunct to chemotherapy planning (specifically, to inform the addition of anti-epidermal growth factor receptor agents, such as cetuximab or panitumumab, among patients with metastatic CRC) ( 18, 19 ) , emphasizing the relevance of this molecular marker in clinical practice. Since KRAS mutations are thought to occur at the early adenoma stage ( 17 ) , it seems biologically plausible that exposures associated with both invasive and preinvasive disease might diff erentially modulate CRC risks based on the KRAS mutation status. Laboratory experiments have also shown that carcinogens found in tobacco smoke can induce cancer-related base substitutions, such as G:C → A:T transitions, in ras oncogenes ( 16, 20 ) . However, to date, relatively few epidemiological studies have examined associations between cigarette smoking and KRAS -defi ned CRC risks ( 9 -13 ) , including only one previous report from a prospective, population-based cohort study ( 13 ) .
For the current report, we utilized data and tissue resources from the Iowa Women ' s Health Study (IWHS), a prospective cohort study of cancer end points among older women, to examine associations between smoking habits and incident CRC by KRAS mutation status (negative or positive). KRAS -defi ned CRC risks were further evaluated with respect to anatomic subsite (proximal colon and distal colorectum), as another potential indicator of subtype-specifi c associations. Th ese data extend prior analyses of cigarette smoking and CRC risk within the IWHS cohort ( 5,21 ) by including additional follow-up time and novel molecular marker associations.
METHODS
Approvals for the present study were obtained from the Institutional Review Boards for Human Research at Mayo Clinic Rochester, the University of Minnesota, and the University of Iowa.
Subjects
Details regarding the methods used for recruitment and enrollment of IWHS participants have been previously reported ( 22 ) . Briefl y, a 16-page baseline questionnaire was mailed out in January 1986 to 99,826 randomly selected women, ages 55 -69 years, who resided in Iowa and held a valid driver ' s license. A total of 41,836 women (42 % ) returned the baseline questionnaire and these subjects constitute the parent IWHS cohort. As reported by Bisgard et al. ( 23 ) , demographic characteristics and CRC rates were similar for the initial survey responders and nonresponders. Vital status and state of residence were determined by mailed follow-up questionnaires in 1987, 1989, 1992, 1997, and 2004 , as well as through linkage to Iowa death certifi cate records. Non-respondents were checked via the National Death Index to identify descendents. For the current analyses, women with a history of malignancy other than skin cancer ( n = 3,830), unable to be followed longitudinally for at least 1 day ( n = 10), or incomplete characterization of cigarette smoking at baseline ( n = 660) were excluded (not mutually exclusive), leaving 37,399 women in the fi nal analytic cohort.
Risk factor assessment
Cigarette smoking patterns among IWHS participants were ascertained at baseline in 1986, including smoking status (never, ever (former or current)), age at smoking initiation (years), smoking duration (years), average number of cigarettes smoked per day, cumulative pack-years, and induction period (diff erence between the baseline date and age at smoking initiation). Potential confounding factors were also derived from the baseline questionnaire, including body mass index; waistto-hip ratio; physical activity level; exogenous estrogen use; and daily intake of total calories, total fat, red meat, calcium, folate, methionine, vitamin E, sucrose, and alcohol. Family history of CRC and non-steroidal anti-infl ammatory drug use were not systematically recorded at baseline and therefore were not included in this study. However, since neither of these factors has been associated with smoking status (to our knowledge), the potential for confounding from these unmeasured variables seems remote.
Case ascertainment
Incident CRC cases were identifi ed through the Iowa Cancer Registry, which participates in the National Cancer Institute ' s SEER (Surveillance, Epidemiology, and End Results) program ( 24 ) . Annual matching between a computer-generated list of all IWHS cohort members and SEER registry data was completed using combinations of fi rst, last, and maiden names; zip code; birth date; and social security number. Data from follow-up surveys indicate that the migration rate out of the IWHS cohort is < 1 % annually, allowing for near-complete follow-up of cancer-related end points ( 25 ) . Incident CRC cases were identifi ed by ICD-O codes, with cancers located in the cecum, ascending colon, hepatic fl exure, transverse colon, and splenic fl exure (ICD-O codes 18.0, 18.2 -18.5) categorized as proximal colon and cancers located in the descending colon, sigmoid colon, rectosigmoid junction, and rectum (ICD-O codes 18.6, 18.7, 19.9, 20.9) categorized as distal colorectum ( 26, 27 
Tissue selection and DNA extraction
Paraffi n blocks were serially sectioned in 5 or 10 μ m increments. One slide was stained with hematoxylin and eosin, and areas of normal and neoplastic (defi ned as ≥ 50 % dysplastic cells in the fi eld of view) tissue were identifi ed. Tumor and normal tissue samples were scraped from unstained slides and placed into separate tubes for DNA extraction, according to manufacturer ′ s instructions (Qiagen, Valencia, CA).
Characterization of KRAS mutation status
Th e tumor DNA was PCR amplifi ed with primers for exon 2 (codons 12 and 13). Th ermocycler conditions were 95 ° C for 10 min, followed by 35 cycles of 95 ° C for 30 s, 60 ° C for 30 s, and 72 ° C for 30 s. Th ere was a fi nal extension for 10 min at 72 ° C. Th e PCR product was cleaned using Shrimp Alkaline Phosphatase and Exonuclease I. Next, the product was sequenced using the Applied Biosystems PRISM BigDye Terminator v1.1 cycle sequencing kit per directions on an ABI PRISM 3730 DNA analyzer (ABI, Carlsbad, CA). Data analysis was performed using the Mutation Surveyor soft ware (Soft Genetics, State College, PA). KRAS mutation status (wild-type vs. specifi c mutation) was determined for 507 (91.4 % ) of the available 555 CRC cases. Positive results for 30 of the 555 cases were confi rmed using the DxS KRAS Mutation Test Kit (Qiagen), which utilizes fl uorescent, allele specifi c real-time quantitative PCR to detect seven point mutations in the KRAS oncogene on the LC 480 (Roche, Indianapolis, IN) instrument.
Statistical analysis
Data were descriptively summarized using frequencies and percentages for categorical variables and means and standard deviations for continuous variables. Measures of agreement across molecularly defi ned tumor subtypes of CRC were examined by use of kappa coeffi cients. Follow-up was calculated as age at completion of the baseline survey until age at fi rst CRC diagnosis, age at move from Iowa, or age at death. If none of these events occurred, a woman was assumed to be alive, cancer free, and living in Iowa through 31 December 2002. Cox proportional hazard regression analysis was used to estimate relative risks (RRs) and 95 % confi dence intervals (CIs) for associations between cigarette smoking exposures and incident CRC outcomes.
All eligible IWHS participants were included in the Cox regression analyses, regardless of eventual cancer status. Incidence was modeled as a function of age because age is a better predictor of cancer risk in our cohort than follow-up time ( 28 ) . We assessed the eff ects of smoking status (never, ever, former, or current), age at smoking initiation ( > 30 or ≤ 30 years), total smoking duration analyses, never smokers were modeled as the reference group. Tests for trend were carried out for each smoking variable by ordering the categorized values from lowest to highest category and including the resulting variable as a linear term with 1 df in a Cox proportional hazards model. Th e Cox regression proportionality assumption was formally evaluated by fi tting and testing a smoking-by-time interaction term.
Smoking associations were examined with respect to CRC subsets defi ned by KRAS mutation status (mutation negative or mutation positive) and anatomic subsite (proximal colon or distal colorectum). Th e outcome variable was incident CRC with the KRAS mutation status of interest; all other CRC cases (including those with missing or unknown KRAS mutation status) were considered censored observations at the date of fi rst diagnosis. We also examined associations between cigarette smoking and incident CRC, based on the tissue availability status (available or not available) by using the same multi-outcome analytic approach as described above to determine whether incomplete tissue collection introduced any possible association biases. Two sets of Cox regression models were fi t, one accounting for age and one adjusting for age and other potential confounding factors were body mass index (quartiles); waist-to-hip ratio (quartiles); physical activity level (low, moderate, or high); exogenous estrogen use (never or ever); and daily intake (quartiles) of total calories (kcal / day), total fat (g / day), red meat (g / day), calcium (mg / day), folate ( μ g / day), methionine (g / day), vitamin E (mg / day), sucrose (g / day), and alcohol (0, 0 -3.4, or >3.4 g / day). We also formally determined whether risk estimates for the smoking-related variables diff ered across KRAS -defi ned CRC subtypes using a competing risk form of Cox proportional hazards regression ( 29 ) . Th is approach allowed us to specifi cally model and test the inter action between smoking (modeled as a covariate) and CRC subtype (included as a Cox regression stratum variable). All statistical tests were two-sided, and all analyses were carried out with the SAS (SAS Institute, Cary, NC) and S-Plus ( 
RESULTS
Smoking status was characterized as never, former, and current for 24,638 (66 % ), 7,208 (19 % ), and 5,553 (15 % ) IWHS subjects, respectively. At baseline, never smokers were slightly older than either former or current smokers (mean ages 62.4, 61.9, and 61.4 years; P < 0.01). Current smokers had a lower body mass index (25.3 kg / m 2 ) compared with never (27.3 kg / m 2 ) or former (27.2 kg / m 2 ) smokers. Other baseline characteristics also diff ered by smoking status including waist-to-hip ratio, physical activity level, exogenous estrogen use, and daily intakes of total energy, total fat, red meat, calcium, folate, methionine, vitamin E, sucrose, and alcohol ( P < 0.01 for each variable, except P = 0.03 for vitamin E; Table 1 ).
Among the 507 CRC cases for which KRAS status could be classifi ed, the molecular subtype distribution was 342 (67 % )
COLON/SMALL BOWEL

Cigarette Smoking and CRC Risk by KRAS Mutation Status Among Older Women
mutation-negative and 165 (33 % ) mutation-positive tumors. Th e agreement between KRAS mutation status and other molecular subtypes was MSH-H, κ = 0.25; CpG island methylator phenotype positive, κ = 0.27; and BRAF mutation positive, κ = 0.31. Multivariate-adjusted risk estimates for associations between cigarette smoking and incident CRC, stratifi ed by KRAS mutation status, are presented in Table 2 (age-adjusted risk estimates were gene rally similar; data not shown). In general, smoking-related risk estimates were higher for KRAS mutation-negative than for KRAS mutation-positive tumors. Tests for trend across age at initiation ( P trend = 0.02), average number of cigarettes per day ( P trend = 0.01), cumulative pack-years ( P trend = 0.05), and induction period ( P trend = 0.04) exposure levels were statistically signifi cant for KRAS mutation-negative tumors. Positive associations were also observed for KRAS mutation-negative tumors with smoking status ( P trend = 0.08) and total smoking duration ( P = 0.06), but the trend tests were not statistically signifi cant. Women who smoked an average of ≥ 40 cigarettes per day were at the highest risk for KRAS mutation-negative tumors (RR = 2.38; 95 % CI = 1.25 -4.51, compared with never smokers). In contrast, none of the smoking variables were signifi cantly associated with KRAS mutation-positive CRCs. Of note, tests for heterogeneity in the smoking-related risk estimates across levels of KRAS mutation status were not statistically signifi cant ( P > 0.05 for each comparison), likely due in part to power limitations imposed by the available sample size.
Further analyses were conducted to explore smoking-related associations with incident CRCs defi ned by both KRAS mutation status and anatomic subsite ( Table 3 ). For KRAS mutation-negative tumors located in the proximal colon, statistically signifi cant risks were observed with smoking status ( P trend = 0.04), age at initiation ( P = 0.03), and average number of cigarettes per day ( P trend = 0.01). Conversely, null associations were observed between the analyzed smoking variables and KRAS mutation-negative tumors located in the distal colorectum, as well as KRAS mutationpositive tumors located in either the proximal colon or distal colorectum. Of note, relatively small event rates minimized our ability to obtain robust risk estimates for some of the KRAS -defi ned, subsite-specifi c CRC associations. In analyses defi ning cases as only those with available tissue, results comparing ever smokers with never smokers (RR = 1.19; 95 % CI = 1.00 -1.42, P = 0.05) were similar to those based on all incident cases (RR = 1.20, 95 % CI = 1.07 -1.35, P = 0.003), supporting a low likelihood of selection bias introduced by tissue availability status.
DISCUSSION
In this large prospective cohort study of older women, cigarette smoking was more closely associated with incident CRCs characterized by KRAS mutation-negative, rather than KRAS mutation-positive, status. Consistent (though not always statistically signifi cant) trends were observed across all categories of cigarette smoking exposure, with intensity (i.e., average number of cigarettes per day), duration, and induction period demonstrating the strongest associations with KRAS mutation-negative tumors. Findings from the current study complement our previous report of differential associations between cigarette smoking and CRC subtypes defi ned by microsatellite instability, CpG island methyl ator phenotype, or BRAF mutation status in the IWHS cohort ( 5 ) . Together, these data support the hypothesis that cigarette smoking aff ects CRC risk through the serrated pathway of carcinogenesis ( 30 ). smoking exposure of ≥ 20 cigarettes per day was reportedly associated with a 50 % increased risk for KRAS mutation-negative tumors among men (OR = 1.5; 95 % CI = 1.2 -1.9), although a null association was observed among women (OR = 1.1; 95 % CI = 0.8 -1.4) ( 11 ). A subsequent report from the Slattery group ( 9 ) demonstrated no apparent association between active smoking
Existing data on KRAS -defi ned CRC risks among cigarette smokers and non-smokers are limited and inconsistent across studies ( 9 -13,15 ) . Consistent with our fi ndings, Slattery et al. ( 11 ) reported no statistically signifi cant associations between cigarette smoking and KRAS mutation-positive colon cancers among men or women in a multicenter case -control study. However, CI, confi dence interval; RR, relative risk. a Do not always sum to total due to missing smoking data. b Adjusted for age, body mass index, waist-to-hip ratio, physical activity level, alcohol consumption, exogenous estrogen use, and daily intake of total calories, fat, sucrose, red meat, calcium, folate, vitamin E, and methionine.
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and KRAS mutation-positive rectal cancer, although subjects who described long-term exposure to environmental tobacco smoke of >10 h per week were at increased risk for this KRAS -mutated rectal cancer (OR = 1.50; 95 % CI = 1.04 -2.20). In the only other prospective study reported to date, Weijenberg et al. ( 13 ) analyzed CRC specimens from a subset of Netherlands Cohort Study participants ( n = 648 cases and 4,083 subcohort controls). Ex-smokers were found to be at increased risk for KRAS mutation-negative tumors non-Caucasian subjects), which will require further investigation in more diverse subject populations. Second, we were unable to retrieve adequate tissue specimens from all IWHS subjects with incident CRC for the planned molecular analyses. However, as noted above, tissue availability biases did not appear to infl uence the smoking-related, molecularly defi ned CRC risk estimates. Th ird, our sample sizes were relatively low in some of the CRC subsets defi ned by combinations of KRAS mutation status and anatomic subsite. Although we did fi nd a statistically signifi cant association between cigarette smoking and KRAS mutation-negative tumors arising from the proximal colon, it remains possible that associations based on other subtype / subsite combinations went undetected. In summary, data from this prospective cohort study of older women suggest that cigarette smoking is associated with molecularly distinct CRC subtypes, which can be defi ned, in part, by KRAS mutation-negative status. Th ese fi ndings support a possible causative eff ect from tobacco exposure on KRAS -independent mechanisms of colorectal carcinogenesis, perhaps through methylation-induced silencing of DNA mismatch repair genes (and / or other growth regulating genes), resulting in tumors with the serrated pathway phenotype. Further investigation of smoking-related CRC risks based on other molecular markers and integrated pathways is ongoing in the IWHS cohort, which should yield additional insights regarding the mechanisms of carcinogenesis induced by this common, potentially modifi able exposure.
(RR = 1.79; 95 % CI = 1.00 -3.20), but not for KRAS mutationpositive tumors (RR = 1.20; 95 % CI = 0.61 -2.33). Current smokers were not at signifi cantly increased risk for either of the KRASdefi ned CRC subtypes.
Other previous observational studies have described slightly diff erent KRAS -specifi c CRC risk associations than we observed in the IWHS cohort. Diergaarde et al. ( 15 ) conducted a Dutch population-based, case -control study, which showed no signifi cant diff erence between risks for KRAS mutation-positive or KRAS mutation-negative colon cancers among ever vs. never smokers (OR = 1.4; 95 % CI = 0.7 -2.8 and OR = 0.8; 95 % CI = 0.5 -1.4, respectively). Using a diff erent study design, Miyaki et al. ( 14 ) compared the prevalence of KRAS mutations in CRCs analyzed from a small group of cigarette smokers ( n = 28) and non-smokers ( n = 33), with no statistically signifi cant diff erence detected between groups (32 vs. 39 % ; P = 0.38). In an attempt to clarify the relationship between cigarette smoking, KRAS mutation, and colorectal neoplasia risk, Porta et al. ( 16 ) performed a meta-analysis of available observational data (including two studies with adenoma rather than adenocarcinoma end points) ( 10, 12 ) . Th e summary risk estimate for the association between tobacco use and KRAS mutation-positive tumors was not statistically significant (RR = 0.96; 95 % CI = 0.83 -1.13). However, no risk estimate for KRAS mutation-negative tumors was reported. Although not conclusive, data from the Netherlands Cohort Study and the IWHS (at least) suggest that further evaluation of cigarette smoking eff ects on KRAS -independent pathways of colorectal carcinogenesis may be informative.
Data from our study revealed statistically signifi cant associations between smoking indicators and KRAS -defi ned, subsitespecifi c CRC risks. Conversely, in the Netherlands Cohort Study, smoking-related risk estimates for KRAS mutation-positive and KRAS mutation-negative tumors were reportedly similar when analyzed by colon, rectosigmoid, and rectal subsites ( 13 ) . However, as with our study, small case numbers limited accurate risk assessment for some of the subgroup analyses. Interestingly, neoplasms arising through the serrated pathway of carcinogenesis ( 30 ) are typically characterized by a proximal colonic location, microsatellite instability-high, CpG island methylator phenotype-high and BRAF mutation-positive status, and absence of KRAS mutations. Th ese clinical and molecular features are consistent with the smoking-related associations reported in the current study, as well as in previous IWHS reports ( 5, 31 ) . Of note, other studies have also described limitations in colonoscopy-based screening and surveillance algorithms for reducing CRC risk in the proximal colon ( 32, 33 ) and among active smokers ( 34 ) . Coupled with our observations, further consideration of modifi ed CRC early detection strategies tailored specifi cally to cigarette smokers seems indicated.
Major strengths of our study include the prospective design, detailed exposure data, prolonged follow-up time, near-complete case ascertainment, CRC tissue availability, and high-quality KRAS mutation analyses. Potential limitations should also be acknowledged. First, the reported fi ndings cannot be directly extrapolated to other demographic subgroups (e.g., younger women, men, and
